23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › ADAPTIVE BIOTECHNOLOGIES CORP. › 2023-2024

ADAPTIVE BIOTECHNOLOGIES CORP. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings. Page generated November 20, 2026.

  • 5Reported items
  • 203Asset managers, any item
  • 1,002Fund votes
  • June 7, 2024Meeting date

Results at a glance

No official results are on file for this meeting: no Form 8-K tally (Item 5.07) from ADAPTIVE BIOTECHNOLOGIES CORP. has been matched to it. The figures below are the funds’ own votes from Form N-PX. They are not the meeting result, so they are not used to judge dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ADAPTIVE BIOTECHNOLOGIES CORP. in the interactive database Compare manager voting policies

How asset managers voted at the ADAPTIVE BIOTECHNOLOGIES CORP. 2023-2024 meeting

203 asset managers disclosed a vote on at least one ADAPTIVE BIOTECHNOLOGIES CORP. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ADAPTIVE BIOTECHNOLOGIES CORP.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

To elect two Class II director nominees to serve on the board of directors of Adaptive Biotechnologies…: Peter Neupert

No official resultsDIRECTOR ELECTIONS

Combines 4 wordings of this item as funds reported it.

60% of fund votes cast · no official result

FORWITHHOLD
Details: description as filed, votes by 59 asset managers

Description as filed by funds: To elect two Class II director nominees to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2027 annual meeting of shareholders: Peter Neupert

The 59 asset managers below reported 23,845,865 for, 15,683,447 withheld. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 23,845,865WITHHOLD: 15,683,447
Largest asset managers voting on “To elect two Class II director nominees to serve on the board of directors of Adaptive Biotechnologies Corpora” at ADAPTIVE BIOTECHNOLOGIES CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard12,805,1160 00For
ARK ETF Trust10,319,6350 00For
MFS00 03,329,532Withhold
BlackRock00 02,940,769Withhold
Fidelity00 02,437,190Withhold
Aberdeen00 01,029,447Withhold
Federated Hermes00 0910,597Withhold
Charles Schwab00 0870,224Withhold
Aristotle Funds Series Trust00 0829,708Withhold
Dimensional00 0704,002Withhold
TIAA00 0549,742Withhold
Prudential/PGIM112,6120 0237,483Mixed
Equitable00 0292,368Withhold
Pacific Life00 0291,982Withhold
Putnam219,3460 00For
Goldman Sachs00 0190,752Withhold
Dunham Funds117,3460 00For
Lincoln Financial2,3690 0107,207Withhold
PRIMECAP Odyssey Funds104,2300 00For
RBB FUND, INC.101,9320 00For
PFM Multi-Manager Series Trust00 090,980Withhold
T. Rowe Price00 080,946Withhold
1290 Funds00 071,325Withhold
Northern Trust00 070,987Withhold
JPMorgan63,2110 00For

Showing the 25 largest of 59 asset managers. All 59 are in the interactive database (link above).

To elect two Class II director nominees to serve on the board of directors of Adaptive…: Michelle Griffin

No official resultsDIRECTOR ELECTIONS

Combines 4 wordings of this item as funds reported it.

82% of fund votes cast · no official result

FORWITHHOLD
Details: description as filed, votes by 59 asset managers

Description as filed by funds: To elect two Class II director nominees to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2027 annual meeting of shareholders: Michelle Griffin

The 59 asset managers below reported 32,315,659 for, 7,213,653 withheld. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 32,315,659WITHHOLD: 7,213,653
Largest asset managers voting on “To elect two Class II director nominees to serve on the board of directors of Adaptive Biotechnologies Corpora” at ADAPTIVE BIOTECHNOLOGIES CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard12,805,1160 00For
ARK ETF Trust10,319,6350 00For
MFS00 03,329,532Withhold
BlackRock2,940,7690 00For
Fidelity2,329,7820 0107,408For
Aberdeen00 01,029,447Withhold
Federated Hermes910,5970 00For
Charles Schwab870,2240 00For
Aristotle Funds Series Trust00 0829,708Withhold
Dimensional00 0704,002Withhold
TIAA549,7420 00For
Prudential/PGIM112,6120 0237,483Mixed
Equitable177,1720 0115,196Mixed
Pacific Life39,7960 0252,186Mixed
Putnam219,3460 00For
Goldman Sachs190,7520 00For
Dunham Funds117,3460 00For
Lincoln Financial100,4690 09,107Mixed
PRIMECAP Odyssey Funds104,2300 00For
RBB FUND, INC.101,9320 00For
PFM Multi-Manager Series Trust00 090,980Withhold
T. Rowe Price00 080,946Withhold
1290 Funds00 071,325Withhold
Northern Trust70,9870 00For
JPMorgan63,2110 00For

Showing the 25 largest of 59 asset managers. All 59 are in the interactive database (link above).

To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy…

No official resultsFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 9 wordings of this item as funds reported it.

84% Fund and manager reports combined; may count the same shares twice · no official result

FORAGAINST
Details: description as filed, votes by 201 asset managers

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement;

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 59 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in ” at ADAPTIVE BIOTECHNOLOGIES CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard12,777,01628,100 00For
ARK ETF Trust10,319,6350 00For
MFS3,329,5320 00For
BlackRock02,940,769 00Against
Fidelity2,387,74049,450 00For
Aberdeen01,029,447 00Against
Federated Hermes0910,597 00Against
Charles Schwab0870,224 00Against
Aristotle Funds Series Trust829,7080 00For
Dimensional0704,002 00Against
TIAA549,7420 00For
Prudential/PGIM237,483112,612 00Mixed
Equitable115,196177,172 00Mixed
Pacific Life252,18639,796 00Mixed
Putnam0219,346 00Against
Goldman Sachs190,7520 00For
Dunham Funds117,3460 00For
Lincoln Financial98,10011,476 00Mixed
PRIMECAP Odyssey Funds0104,230 00Against
RBB FUND, INC.101,9320 00For
PFM Multi-Manager Series Trust90,9800 00For
T. Rowe Price80,9460 00For
1290 Funds71,3250 00For
Northern Trust70,9870 00For
JPMorgan063,211 00Against

Fund voting reports, all 59 managers: 32,048,827 for, 7,457,597 against, 22,888 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 162 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in ” at ADAPTIVE BIOTECHNOLOGIES CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
VIKING GLOBAL INVESTORS LP29,993,7080 00For
Rubric Capital Management LP10,119,8450 00For
Matrix Capital Management Company, LP5,522,3180 00For
Nikko Asset Management Americas, Inc.4,182,3930 00For
BlackRock123,6343,953,586 00Against
MASSACHUSETTS FINANCIAL SERVICES CO /MA/3,819,2010 00For
GEODE CAPITAL MANAGEMENT, LLC2,440,0020 00For
State Street2,252,7320 00For
Nikko Asset Management Co., Ltd.1,994,3140 00For
PICTET ASSET MANAGEMENT SA1,744,1070 00For
Man Group plc01,510,880 00Against
Federated Hermes01,311,888 00Against
Aristotle Atlantic Partners, LLC1,130,7040 00For
Aberdeen01,029,447 00Against
BRAIDWELL LP969,3460 00For
Putnam0958,660 00Against
Charles Schwab0870,547 00Against
DDD Partners, LLC0744,985 00Against
Pier Capital, LLC651,0890 00For
Northern Trust594,86078 00For
Nuveen553,7610 00For
MELLON INVESTMENTS Corp530,4510 00For
Dimensional0312,116 00Against
Goldman Sachs270,8430 00For
Vanguard267,7820 00For

Institutional-manager reports, all 162 managers: 69,452,196 for, 11,836,650 against, 7,524 not voted, 214 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Advisory Vote to Ratify Named Executive Officers' Compensation

No official resultsSECTION 14A SAY-ON-PAY VOTES

2% of fund votes cast · no official result

AGAINST
Details: votes by 3 asset managers

The 3 asset managers below reported 21,608 for, 974,170 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 21,608AGAINST: 974,170
Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at ADAPTIVE BIOTECHNOLOGIES CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
NORDEA INVESTMENT MANAGEMENT AB0859,214 00Against
JPMorgan0114,956 00Against
ESSEX INVESTMENT MANAGEMENT CO LLC21,6080 00For

To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending…

No official resultsAUDIT-RELATED

Combines 3 wordings of this item as funds reported it.

100% of fund votes cast · no official result

FOR
Details: description as filed, votes by 59 asset managers

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024; and

The 59 asset managers below reported 39,506,424 for, 22,888 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 39,506,424ABSTAIN: 22,888
Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the ye” at ADAPTIVE BIOTECHNOLOGIES CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard12,805,1160 00For
ARK ETF Trust10,319,6350 00For
MFS3,329,5320 00For
BlackRock2,940,7690 00For
Fidelity2,437,1900 00For
Aberdeen1,029,4470 00For
Federated Hermes910,5970 00For
Charles Schwab870,2240 00For
Aristotle Funds Series Trust829,7080 00For
Dimensional704,0020 00For
TIAA549,7420 00For
Prudential/PGIM350,0950 00For
Equitable292,3680 00For
Pacific Life291,9820 00For
Putnam219,3460 00For
Goldman Sachs190,7520 00For
Dunham Funds117,3460 00For
Lincoln Financial109,5760 00For
PRIMECAP Odyssey Funds104,2300 00For
RBB FUND, INC.101,9320 00For
PFM Multi-Manager Series Trust90,9800 00For
T. Rowe Price80,9460 00For
1290 Funds71,3250 00For
Northern Trust70,9870 00For
JPMorgan63,2110 00For

Showing the 25 largest of 59 asset managers. All 59 are in the interactive database (link above).

Largest ADAPTIVE BIOTECHNOLOGIES CORP. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 147,368,324 shares outstanding at the time of that meeting.

Fund voting reports: top ADAPTIVE BIOTECHNOLOGIES CORP. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of our named executive officers…”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 8.69%
2ARK ETF Trust 7.00%
3MFS 2.26%
4BlackRock 2.00%
5Fidelity 1.65%
6Aberdeen 0.70%
7Federated Hermes 0.62%
8Charles Schwab 0.59%
9Aristotle Funds Series Trust 0.56%
10Dimensional 0.48%
Institutional-manager reports: top ADAPTIVE BIOTECHNOLOGIES CORP. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of our named executive officers…”, 2023-2024
#Asset manager % of shares outstanding
1VIKING GLOBAL INVESTORS LP 20.35%
2Rubric Capital Management LP 6.87%
3Matrix Capital Management Company, LP 3.75%
4Nikko Asset Management Americas, Inc. 2.84%
5BlackRock 2.77%
6MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 2.59%
7GEODE CAPITAL MANAGEMENT, LLC 1.66%
8State Street 1.53%
9Nikko Asset Management Co., Ltd. 1.35%
10PICTET ASSET MANAGEMENT SA 1.18%

Reported ADAPTIVE BIOTECHNOLOGIES CORP. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

ADAPTIVE BIOTECHNOLOGIES CORP. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Viking Global Entities29,993,708 20.35%Proxy statement (DEF 14A)
BlackRock13,357,977 9.06%Form 13F, quarter ended March 31, 2024
ARK Investment Management LLC12,806,513 8.69%Schedule 13G, filed January 29, 2024
Matrix Capital Management Master Fund, LP11,572,590 7.85%Proxy statement (DEF 14A)
Vanguard Group11,275,169 7.65%Form 13F, quarter ended March 31, 2024
Chad Robins4,016,889 2.73%Proxy statement (DEF 14A)
State Street2,680,546 1.82%Form 13F, quarter ended March 31, 2024
Goldman Sachs1,879,852 1.28%Form 13F, quarter ended March 31, 2024
Harlan Robins, PhD1,795,360 1.22%Proxy statement (DEF 14A)
Julie Rubinstein1,114,027 0.76%Proxy statement (DEF 14A)

Percentages above are of 147,368,324 shares outstanding, as reported by ADAPTIVE BIOTECHNOLOGIES CORP. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At ADAPTIVE BIOTECHNOLOGIES CORP.'s shareholder meeting held June 7, 2024, in the 2023-2024 proxy season, 203 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,002 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. No official Form 8-K vote tally has been matched to this meeting, so this page states no certified outcome for its most widely held ballot item. On that item — To approve, on a non-binding advisory basis, the compensation of our named executive officers… — the reporting funds and managers cast 84% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ADAPTIVE BIOTECHNOLOGIES CORP.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

ADAPTIVE BIOTECHNOLOGIES CORP. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “ADAPTIVE BIOTECHNOLOGIES (ADPT) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/adaptive-biotechnologies-corp/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.